Andere Kunden interessierten sich auch für
![Mesoporous silica and magnetic nanoparticle based controlled release]( "Mesoporous silica and magnetic nanoparticle based controlled release")
Mesoporous silica and magnetic nanoparticle based controlled release26,99 €![Hydrophilic Matrix Tablets for Oral Controlled Release]( "Hydrophilic Matrix Tablets for Oral Controlled Release")
Hydrophilic Matrix Tablets for Oral Controlled Release110,99 €![Controlled Release in Oral Drug Delivery]( "Controlled Release in Oral Drug Delivery")
Controlled Release in Oral Drug Delivery147,99 €![Hydrophilic Matrix Tablets for Oral Controlled Release]( "Hydrophilic Matrix Tablets for Oral Controlled Release")
Hydrophilic Matrix Tablets for Oral Controlled Release110,99 €![Handbook of Encapsulation and Controlled Release]( "Handbook of Encapsulation and Controlled Release")
Handbook of Encapsulation and Controlled Release628,99 €![Nanocarriers for Controlled Release and Target Delivery of Bioactive Compounds]( "Nanocarriers for Controlled Release and Target Delivery of Bioactive Compounds")
Nanocarriers for Controlled Release and Target Delivery of Bioactive Compounds30,99 €![Mechanisms of polymer matrix formation in sustained release tablets]( "Mechanisms of polymer matrix formation in sustained release tablets")
Mechanisms of polymer matrix formation in sustained release tablets51,99 €
The present investigation involves development of a CR Nifedipine microparticulate system utilizing starch acetate as the rate controlling polymer. SA was manufactured in house form native starches and characterization for degree of substitution (dS) and acetyl content among other parameters. An emulsification solvent evaporation technique was followed to develop microparticles of varying drug- polymer ratio's with triethyl citrate plasticizers at different levels. The prepared microparticles were subjected to standard evaluation such as yield, particle size, surface topography, drug content and in vitro dissolution studies.The development formulations were subsequently optimized through a simplex lattice mixture design to predict the optimum formulations matching the target official release profiles. It was found that two blend of development formulations, namely F1: F5 (0.822:0.1780) and F5: F13 (0.041:0.959) could closely resemble official specification and hence were optimum.The developed multiparticulate systems of Nifedipine are expected to provide a better clinical option for treatment of persistent/chronic angina and hypertension.